Alterations of the muscarinic cholinergic (mACh) receptors in the striatum of the MPTP-induced parkinsonian model in mice: in vitro quantitative autoradiographical analysis.
The alteration of muscarinic cholinergic (mACh) receptors in the striatum of mice after administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was examined using a [3H]quinuclidinyl benzilate [( 3H]QNB) in vitro labeling macro-autoradiographic technique and mACh receptor concentration was quantitatively analyzed using a computer analysis system. Two weeks after cessation of MPTP administration, the striatal mACh receptors were significantly increased. In the subchronic phase, at 6 weeks, the striatal mACh receptors were significantly decreased but recovered to the normal level by the treatment with L-dihydroxyphenylalanine (L-DOPA) for two weeks before sacrifice. These findings indicated that the striatal mACh receptors are strongly regulated by the nigrostriatal dopaminergic function.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001345:Autoradiography; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010300:Parkinson Disease / Q000378:metabolism*; D011725:Pyridines / Q000633:toxicity*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium
D011725:Pyridines; D011976:Receptors, Muscarinic; D014316:Tritium; D011813:Quinuclidinyl Benzilate; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine